sGC activators, such as cinaciguat, increases cGMP levels by direct, NO-independent activation of sGC, and may be particularly effective in conditions of increased oxidative stress and endothelial dysfunction, and therefore reduced NO levels, but this comes at the expense of a greater risk of hypotension. The gene discussed is SGCB; the disease is endothelial dysfunction.